Growth factor regulation of fracture repair. Barnes GL, Kostenuik PJ, Gerstenfeld LC, and Einhorn TA. J Bone Miner Res 14: 1805-1815, 1999. PMID: 10571679

The effects of osteoprotegerin on the mechanical properties of rat bone. Ross AB, Bateman TA, Kostenuik PJ, Lacey DL, Dunstan CR, Ferguson VL, Simske SJ. J Mat Sci: Materials in Medicine 7: 583-588, 2001. PMID: 15348250

RANKL inhibition: A novel strategy to decrease femoral head deformity after ischemic necrosis. Kim HKW, Morgan-Bagley S, Kostenuik PJ. J Bone Miner Res 21: 1946-1954, 2006. PMID: 17002576*

Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. Gerstenfeld LC, Sack DJ, Pelis M, et al. J Bone Miner Res 24: 196-208, 2009. PMID: 19016594.

Sclerostin monoclonal antibody stimulates bone formation and improves the strength and density of the fracture callus and lumbar spine in a primate fibular osteotomy model. Ominsky MS, Samdfam R, Jolette J, Vlasseros F, Smith SY, Kostenuik PJ, Paszty C, Simonet WS, Ke HZ. J Bone Miner Res 24 (Suppl. 1): S89, 2009 (Abstract).

Matrix metalloproteinase-driven endochondral fracture union proceeds independently of osteoclast activity. McDonald MM, Morse A, Mikulec K, Peacock L, Baldock PA, Kostenuik PJ, and Little DG. J Bone Miner Res 28: 1550-1560, 2013. PMID: 23408642.

Crack accumulation and strength loss in fatigue-damaged bone increase when osteoclasts are stimulated and decrease when osteoclasts are inhibited. Bonnet N, Gerbaix M, Kostenuik P, Ominsky M, Ferrari S. J Bone Miner Res 2013;

28 (Suppl 1): S92 (Abstract).

 RANKL and OPG administration influence the pattern and location of fractures created during biomechanical testing of intact and fatigued mouse tibia. Bonnet N, Kostenuik P, Ominsky M, Ferrari S. J Bone Miner Res 2013; 28 (Suppl 1): S211 (Abstract).

Influence of fatigue loading and bone turnover on bone strength and pattern of experimental fractures of the tibia in mice. Bonnet N, Gerbaix M, Ominsky M, et al. Calcif Tissue Int 2016. PMID: 26945756.

Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect.  Bougioukli S, Jain A, Sugiyama O, Tinsley B, Tang H, Tan MH, Adams D, Kostenuik PJ, Lieberman JR.  Bone 84:93-103, 2016. PMID: 26723577

Fracture healing physiology and the quest for therapies for delayed healing and nonunion fractures.
​Kostenuik, PJ, Mirza FM. J Orthop Res 35:213-223, 2017. PMID: 27743449

Abaloparatide, a selective PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with closed femoral fractures.  Lanske B, Chandler H, Pierce A, Brown J, Ominsky MS, Kostenuik PJ, and Hattersley G. J Orthop Res 2019;37:812-820. PMID: 3070359

Immobilization of denosumab on titanium affects osteoclastogenesis of human peripheral blood monocytes. Beck F, Hartmann ES, Kohsler MI, Schlussel S, Redeker JI, Schmitt B, Fottner A, Michael J, Summer B, Kunzelmann K-H, Scharweber D, Kostenuik PJ, and Mayer-Wagner S. Int J Mol Sci 2019;20:1002. PMID: 30813507

Abaloparatide increases bone mineral density in regions corresponding to Gruen Zones 1, 2, 6, and 7 in postmenopausal women with osteoporosis. Sheth NP, Winzenrieth R, Humbert L, Kostenuik PJ, Wang Y, Boxberger JI, Bostrom MP. Hip Society Summer Meeting, Santa Monica, CA, 2022.

​Effects of abaloparatide  versus placebo on bone mineral density in acetabular regions corresponding to DeLee and Charnley zones in postmenopausal women with osteoporosis. Sheth NP, Krohn K, Winzenrieth RW, Humbert L, Pearman L, Wang Y, Caminis J, Boxberger J, and Bostrom M. International Society of Clinical Densitometry  Annual meeting, Chicago, IL, 2023. 

​Abaloparatide increases bone mineral density in regions corresponding to Gruen Zones 1, 2, 6, and 7 in postmenopausal women with osteoporosis. Sheth NP, Winzenrieth R, Humbert L, Kostenuik PJ, Wang Y, Boxberger JI, Bostrom MP. Hip Society Summer Meeting, Santa Monica, CA, 2022.

Dual inhibition of the Wnt inhibitors DKK1 and sclerostin promotes experimental fracture healing and increased the density and strength of non-injured bone: An experimental study in nonhuman primates. Florio M, Kostenuik P, Stolina M, Ascuncion F, Grisanti M, Ke HZ, and Ominsky MS. J Bone Joint Surg 105(15):1145-1155, 2023. PMID: 37159527.

Advances in osteoporosis therapy: Focus on osteoanabolic agents, secondary fracture prevention, and perioperative bone health. Kostenuik P, Binkley N, Anderson P. Curr Osteoporos Rep 21(4):386-400, 2023; PMID : 37289382.

Platelet-rich plasma contains high concentrations of DKK1, a potent inhibitor of Wnt signaling that limits bone regeneration and hair growth. Kostenuik P, Mirza F, Collins M. J Orthopedics & Bone Disorders ​2023 (in press).

​

 Dr. Kostenuik's publications in the orthopedics field

Paul's interest in orthopedic research started as a volunteer instructor in the cadaver lab at Waterloo University, followed by a faculty appointment at Boston University's Department of Orthopedic Surgery where he studied fracture healing. Paul conducted further research on fracture healing and implants at Amgen.
Paul received a Ponseti award from the Pediatric Orthopedic Society
for his work on experimental treatments for Legg-Calve-Perthes
disease (PMID 17002576* below).  He is also the CEO
and co-founder of Ortheus Inc, an orthobiologics
start-up, and a volunteer ambassador 
and fund-raiser for the clubfoot
non-profit MiracleFeet. 

Orthopedics

Dr. Kostenuik's Orthopedics-Related Patents:
PTO 62/665,981 │ Systems and methods for local modulation of Wnt signaling

PCT/US21/62184  |  Fibrin-based bone substitute compositions and methods